This session explores residual cardiovascular risk beyond LDL-C, focusing on the role of elevated triglycerides and the clinical evidence for triglyceride-lowering approaches, including outcomes data, safety considerations, and mechanistic insights. It reviews relevant NICE technology appraisal guidance and NHS lipid optimisation pathways, before examining why some trials in this space have succeeded while others have not, and closing with a discussion of remaining questions around mechanism and clinical uptake.

UK-VAZK-0307, Sept 2026